Atherosclerosis core

动脉粥样硬化核心

• 批准号: 10628989
• 负责人: Edward A Fisher
• 金额: $ 21.49万
• 依托单位: NYU LONG ISLAND SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-01 至 2028-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10628989
• 关键词: Aorta; Arterial Fatty Streak; Arteries; Atherosclerosis; Biogenesis; Bioinformatics; Biology; Biometry; Catabolism; Cell Compartmentation; Cells; Characteristics; Confocal Microscopy; Data; Digestion; Endothelial Cells; Ensure; Family; Gene Expression; Gene Expression Profiling; Genomics; Histologic; Immunohistochemistry; Laboratories; Lesion; Lesion by Morphology; Lipids; Lipoproteins; Macrophage; Metabolic; Molecular; Myeloid Cells; Population; Procedures; Process; Program Research Project Grants; Reproducibility; Research Personnel; Sampling; Services; Stains; Standardization; Techniques; Technology; Tissues; Valsalva sinus; analytical tool; cell type; cost effectiveness; data management; experimental study; histological stains; instrumentation; laser capture microdissection; novel; single-cell RNA sequencing; tissue preparation; transcriptome sequencing

The Atherosclerosis Core (Core 3; C3) will be led by Dr. Edward Fisher and provide Program Project Grant (PPG) investigators with three complementary approaches for analyzing atherosclerotic lesions, lesion macrophages, and gene expression in myeloid cells and tissues investigated in the projects. First, C3 will provide histological staining, immunohistochemistry, and quantification of atherosclerotic lesions. Second, it will provide laser capture microdissection of macrophages and other types of cells in atherosclerotic lesions for analysis of gene expression changes. Third, C3 will provide expertise in aortic digestion to obtain specific cell compartments to provide samples to the NYU Genomic Technology Center (GTC) for RNA sequencing (RNA- seq) and single cell RNA-seq (scRNA-seq) analyses. These `omic' data will then undergo bioinformatic analyses under Core 1, which will oversee Administration, Data Management, Biostatistics, and Bioinformatics.By providing a central laboratory, C3 offers these services with optimal efficiency and cost- effectiveness, avoiding the need for PPG investigators to maintain the required instrumentation in their own laboratories or use expensive commercial services. By centralizing and standardizing procedures, C3 provides a common set of analytical tools to enable a unified understanding of molecular mechanisms involved in pathophysiologic processes of atherosclerosis and the biology of macrophages and endothelial cells. The Specific Aims of C3 are: 1. To provide comprehensive tissue analysis and quantification of atherosclerotic lesions; 2. To provide laser capture microdissection (LCM) of target cells, primarily macrophages, in atherosclerotic lesions for gene expression studies; 3. To prepare aortic tissue (by digestion and FACS) to provide samples to the GTC for RNA-seq and scRNA-seq (with the resulting data to be analyzed by Core 1).

动脉粥样硬化核心（Core 3; C3）将由Edward Fisher博士领导，并提供计划项目赠款 （PPG）使用三种互补方法分析动脉粥样硬化病变，病变的研究者 巨噬细胞在项目中研究了髓样细胞和组织中的基因表达。首先，C3会 提供组织学染色，免疫组织化学和动脉粥样硬化病变的定量。其次，它将 提供激光捕获巨噬细胞和其他类型细胞在动脉粥样硬化病变中的显微解剖 基因表达变化的分析。第三，C3将提供主动脉消化的专业知识以获得特定的细胞 向NYU基因组技术中心（GTC）提供样品进行RNA测序的隔室（RNA- SEQ）和单细胞RNA-SEQ（SCRNA-SEQ）分析。然后，这些“ OMIC”数据将经历生物信息学 核心1下的分析，该分析将监督管理，数据管理，生物统计学和 通过提供中央实验室，C3以最佳效率和成本 - 有效性，避免需要PPG调查人员自己维护所需的仪器 实验室或使用昂贵的商业服务。通过集中和标准化程序，C3提供 一组共同的分析工具，可以使统一的理解分子机制 动脉粥样硬化的病理生理过程以及巨噬细胞和内皮细胞的生物学。这 C3的具体目的是：1。提供动脉粥样硬化的全面组织分析和定量 病变； 2。提供靶细胞的激光捕获显微解剖（LCM），主要是巨噬细胞，在 用于基因表达研究的动脉粥样硬化病变； 3。准备主动脉组织（通过消化和FACS） 为RNA-SEQ和SCRNA-SEQ提供了GTC的样品（以及由Core 1分析的结果数据）。